Pacific Channel releases updated internal analysis of LCT 10/09/2019, page-8

We're we not told a few months back they were using two upcoming conferences to talk to potential venture partners . We never heard how that went so not sure this next trip would be any different . The language used in most LCT communications almost seems apologetic so no surprise to me they have had no success in convincing Medsafe or potential investors . Commminication via the newsletters is driven by shareholders and is kept to an absolute minimum.
I think the LCT board have shown a total unwillingness to communicate and for me do not seem to have a hunger for success and with one exception ( Elliot) also have no personal equity in the consent except their ongoing salaries .
Two positives from the recent newsletter 1. they managed to email it out to registered shareholders - well done !! 2. They didn't ask the ASX for it to be price sensitive ( normally they seem to ensure bad news is price sensitive and good news isn't ) - this one should have been price sensitive imo.
Outside of that I read nothing that gave me the feeling they are a company with a hunger and drive to ever show a return .
Time for a change imo although I agree we do need to understand the background of proposed directors although don't believe they need to be academics - LCT have those .
Been an ongoing investor for 10 years - my patience is exhausted. Diacebell doesn't even get a reference these days even though Diabetes was the original target- even though they still have rights to some countries it Otsuka come good .
Seems like NTCell is going to suffer the same fete and we are being served up the next unrelated work streams to keep some interest up- with an absolute minimum communication on these workstreams also to go on.
Change required - can't do worse !